A Late Prosthetic Mitral Valve Infective Endocarditis Caused by Micrococcus spp. that Fully Recovered by Antibiotics Treatment : A Rare Case
Downloads
Prosthetic valve endocarditis is the most severe form endocarditis with prevalence of 5.7% at 5 years and mortality with medical treatment is 26%-75%. Case Summary: Male, 46 years old, with mechanic mitral prosthetic valve >5 years, hemiparesis sinistra due to embolic stroke >4 weeks prior, was suffering from persistent fever >38,5â° for 2 weeks without heart failure. Three separate blood cultures came positive with Micrococcus spp. and Osler's node was noticed. Echocardiography shown 1.0 cm x 0.9 cm vegetation at mitral prosthetic valve without paravalvular leakage. Patient was assessed as late mitral PVE. Discussion: Gentamycin, Levofloxacin, and Erythromycin were given based on susceptibility test continued by Meropenem as therapy of urinary tract infection based on susceptibility test after second blood culture result was negative. The patient underwent 42 weeks of antibiotics course. The patient was discharged with good condition, no signs and symptoms of infection or heart failure, blood test was within normal limit, no vegetations with prosthetic mitral valve functioned normally. This case shows that late PVE caused by Micrococcus spp. can be treated by 42 weeks course of antibiotics according to microbial susceptibility test.
Habib G, Badano L, Tribouilloy C, et al. Recommendations for the practice of echocardiography in infective endocarditis. European Journal of Echocardiography. 2010; 11: 202-219.
Kadakia S, Moore R, Ehret A, Toyoda Y. Prosthetic Valve Endocarditis. http:/www.avidscience.com. Accessed at March 3rd 2016.
Otto MC, Bonow RO. Valvular Heart Disease : A Companion to Braunwald's Heart Disease Fourth edition. Philadelphia: Elsevier Inc; 2014.
Durst UN, et al. Micrococcus luteus endocarditis : a rare pathogen of valve prosthesis endocarditis. Z Kardiol. 1991.
von Eiff C, Kuhn N, Herrmann M, Weber S, Peters G. Micrococcus luteus as a cause of recurrent bacteremia. The Pediatric infectious disease journal. 1996 Aug 1;15(8):711-3.
Otto MC, Bonow RO. Valvular Heart Disease : A Companion to Braunwald's Heart Disease Fourth edition. Philadelphia: Elsevier Inc; 2014.
Miltiadous G, Elisaf M. Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature. Journal of medical case reports. 2011 Dec;5(1):251.
Pibarot P, Dumesnil JG. Valvular Heart Disease: Changing Concepts inDisease Management. Prosthetic Heart ValvesSelection of the Optimal Prosthesis and Long-Term Management. Circulation. 2009;119:1034-1048.
Loscalzo J. Harrison's Cardiovascular Medicine Second Edition New York: McGraw-Hill Education; 2013.
Braunwald E, Bonow RO, Mann DL, Zipes DP, Libby P. Brauwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: Elsevier Inc; 2015.
Baddour LM, Wilson WR, Bayer AS, Fowler VG et al.Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy and Management of Complications. A Scientific Statement for Healthcare Professionals From the AmericanHeart Association. Circulation Journal. 2015;132:1435-1486.
Flachskampf FA, Wouters PF, Edvardsen T, et al. Recomendations for Transoesophageal Echocardiography : EACVI update 2014. European Heart Journal-Cardiovascular Imaging. 2014(15); 353-365.
Fuster V, Gorlin R, Walsh RA, Harrington RA, Stack RS. Hurst's The Heart. New York: McGraw-Hill Companies, Inc; 2011.
Prendergast BD, Tornos P. Valvular Heart Disease: Changing Concepts in Disease Management. Surgery for Infective EndocarditisWho and When?. Circulation. 2010;121:1141-1152
Firdaus I, Rahajoe UA, Yahya FA, dkk. Panduan Praktik Klinis (PPK) dan Clinical Pathway (CP) Penyakit Jantung dan Pembuluh Darah. Jakarta. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2016.
Nishimura RA, Otto MC, Bonow RO et al. Infective Endocarditis : AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2014; 589-595.
Copyright (c) 2022 Imam Mahbub Zam Zami
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Cardiovascular and Cardiometabolic Journal (CCJ) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
-
Authors who publish with Cardiovascular and Cardiometabolic Journal (CCJ) agree to the following terms:
-
The journal allows the author to hold the copyright of the article without restrictions.
-
The journal allows the author(s) to retain publishing rights without restrictions.
-
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA).